TLSIW (TriSalus Life Sciences, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by TLSIW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | Richard Marshak | Chief Commercial Officer | Sell | — | — |
| 2026-05-18 | David Patience | Chief Financial Officer | Buy | — | — |
| 2026-05-18 | Mats Wahlstrom | Director | Buy | — | — |
| 2026-05-18 | Mary T Szela | CEO and President | Buy | — | — |
| 2026-05-18 | Gary B. Gordon | Director | Buy | — | — |
| 2026-05-18 | Michael P Stansky | Director | Buy | — | — |
| 2026-05-15 | Michael P Stansky | Director | A | — | — |
| 2026-05-15 | Gary B. Gordon | Director | A | — | — |
| 2026-05-15 | KERRY R HICKS | Director | A | — | — |
| 2026-05-15 | DAVID J MATLIN | Director | A | — | — |
| 2026-05-15 | Mats Wahlstrom | Director | A | — | — |
| 2026-05-15 | William Valle | Director | A | — | — |
| 2026-04-20 | Equity AB Frankenius | 10%+ Owner | C | — | — |
| 2026-04-01 | DAVID J MATLIN | Director | C | — | — |
| 2026-03-20 | Mary T Szela | CEO and President | Sell | — | — |
| 2026-03-20 | Richard Marshak | Chief Commercial Officer | Sell | — | — |
| 2026-03-20 | Bryan F. Cox | Chief of Research | Sell | — | — |
| 2026-03-20 | Jennifer Stevens | Chief Regulatory Officer | Sell | — | — |
| 2026-03-20 | Jodi Devlin | Chief of Clinical Operations | Sell | — | — |
| 2026-02-23 | Mary T Szela | CEO and President | Buy | — | — |
| 2026-02-23 | Gary B. Gordon | Director | Buy | — | — |
| 2026-02-23 | William Valle | Director | Buy | — | — |
| 2026-02-23 | David Patience | Chief Financial Officer | Buy | — | — |
| 2026-02-23 | Michael P Stansky | Director | Buy | — | — |
| 2026-02-11 | Michael P Stansky | Director | A | — | — |
| 2025-11-25 | Bryan F. Cox | Chief of Research | A | — | — |
| 2025-11-25 | Richard Marshak | Chief Commercial Officer | A | — | — |
| 2025-11-25 | David Patience | Chief Financial Officer | A | — | — |
| 2025-11-25 | Jodi Devlin | Chief of Clinical Operations | A | — | — |
| 2025-11-25 | Jennifer Stevens | Chief Regulatory Officer | A | — | — |
| 2025-11-25 | Mary T Szela | CEO and President | A | — | — |
| 2025-08-29 | David Patience | Chief Financial Officer | A | — | — |
| 2025-08-15 | David Patience | Chief Financial Officer | A | — | — |
| 2025-06-27 | KERRY R HICKS | Director | A | — | — |
| 2025-06-27 | DAVID J MATLIN | Director | A | — | — |
| 2025-06-27 | William Valle | Director | A | — | — |
| 2025-06-27 | Arjun JJ Desai | Director | A | — | — |
| 2025-06-27 | Mats Wahlstrom | Director | A | — | — |
| 2025-06-27 | Gary B. Gordon | Director | A | — | — |
| 2025-06-27 | Sean Murphy | Director | A | — | — |
| 2025-05-21 | Sean Murphy | Director | A | — | — |
| 2025-05-21 | Jodi Devlin | Chief of Clinical Operations | MIXED | — | — |
| 2025-05-21 | Bryan F. Cox | Chief of Research | MIXED | — | — |
| 2025-05-21 | James Emmett Young | Chief Financial Officer | A | — | — |
| 2025-05-21 | Jennifer Stevens | Chief Regulatory Officer | MIXED | — | — |
| 2025-05-21 | Richard Marshak | Chief Commercial Officer | MIXED | — | — |
| 2025-02-19 | Mary T Szela | CEO AND PRESIDENT | A | — | — |
| 2025-02-19 | Jodi Devlin | Chief of Clinical Operations | A | — | — |
| 2025-02-19 | Richard Marshak | Chief Commercial Officer | A | — | — |
| 2025-02-19 | Bryan F. Cox | CHIEF OF RESEARCH | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,989,748 | — |
| — | Director | 1,640,420 | — |
| — | Director | 1,592,002 | — |
| — | Director | 1,323,210 | — |
| — | CEO and President | 1,065,215 | — |
| — | Director | 624,635 | — |
| — | Chief Manuf, Strategy&Bus Dev. | 481,524 | — |
| — | Chief Financial Officer | 275,757 | — |
| — | Director | 247,176 | — |
| — | Director | 247,127 | — |
| — | Chief of Research | 163,994 | — |
| — | Chief Commercial Officer | 125,101 | — |
| — | Chief Regulatory Officer | 124,110 | — |
| — | Chief of Clinical Operations | 99,409 | — |
| — | Director | 83,241 | — |
| — | Chief Financial Officer | 79,663 | — |
| — | Director | 72,510 | — |
| — | CHIEF MEDICAL OFFICER | 68,587 | — |
| — | Director | 10,040 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TLSIW quote page; the site-wide leaderboard is on the insider transactions hub.